<!DOCTYPE html>
<html lang="en">
@@include('html/head.html',{
"title":"Home"
})

<body>
	@@include('html/header.html',{})
	<main>
		<div class="section-top pt-12">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="wrapper">
							<div class="h1">INFLAMMATION <br>RESOLUTION</div>
							<div class="h2 mb-5">A NEW THERAPEUTIC TARGET</div>
							<p class="text-unique-dark">Latest research including single-molecule transcriptome sequencing demonstrates how a multicomponent, multitarget treatment can potentially promote inflammation resolution and tissue healing. Read below to find out why this is clinically important and how to attend one of our forthcoming events.</p>
							<div class="img-wrap">
								<img src="@img/Micro-Man-1.svg" alt="">
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<section class="critical-process">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="h2">INFLAMMATION RESOLUTION IS A CRITICAL PROCESS</div>
						<p class="critical-process__desrp text-blue-accent">Inflammation resolution is not merely a passive cessation of proinflammatory mechanisms. It is a complex, tightly regulated system of processes that is critical for tissue healing and restoration of function. Important elements include <span class="tooltips"><sup>1–5</sup></span>:</p>
						<div class="critical-process__info d-flex flex-column flex-lg-row justify-content-between pt-6 pb-12">
							<ul class="list-unstyled mb-0">
								<li><strong>Neutrophil influx:</strong> swarming of neutrophils from the blood stream into the injury site</li>
								<li><strong>Lipid mediator class switch:</strong> release of proresolving mediators, such as lipoxins, resolvins, protectins and maresins</li>
								<li><strong>Efferocytosis:</strong> removal of exhausted, mainly apoptotic neutrophils to prevent tissue damage; many are removed by macrophages</li>
							</ul>
							<ul class="list-unstyled mb-0">
								<li><strong>Macrophage phenotype switch:</strong> “reprogramming” triggered by efferocytosis, from a proinflammatory to a proresolution phenotype, contributing towards postresolution immune tolerance and prevention of autoimmunity</li>
								<li><strong>Neutrophil phenotype switch:</strong> “reprogramming” to an anti-inflammatory type, promoting neutrophil reverse migration</li>
							</ul>
						</div>
						<div class="critical-process__air d-flex flex-column flex-lg-row">
							<img class="pb-6 pb-lg-0" src="@img/AIR.png" alt="">
							<div class="ml-lg-20">
								<p class="pb-1">Recently, an Atlas of Inflammation Resolution was created, providing the most detailed understanding of acute inflammation and inflammation resolution to date.</p>
								<a href="##">https://www.sbi.uni-rostock.de/research/projects/detail/62</a>
							</div>
						</div>
						<div class="separator pt-8 pb-6 pt-xl-6">
							<img src="@img/Divider-2.svg" alt="">
						</div>
					</div>
				</div>
			</div>
		</section>
		<section class="treatments pt-8">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="treatments__info pb-8">
							<div class="h2 mb-3">TREATMENTS THAT SUPPRESS INFLAMMATION MAY ALSO SUPPRESS ITS RESOLUTION</div>
							<p class="text-blue-accent pb-3">In severe conditions, an anti-inflammatory strategy is mandatory to prevent tissue destruction or an overwhelming inflammatory process. Alternatively, a proresolution strategy could be considered the treatment of choice.<span class="tooltips"><sup>6</sup></span></p>
							<p class="text-blue-accent">Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibiting the cyclooxygenase-2 (COX-2) pathway are a mainstay of inflammation treatment. COX-2 promotes biosynthesis of many proinflammatory mediators, but some are equally important for initiation of inflammation resolution.<span class="tooltips"><sup>2</sup></span></p>
							<p class="py-5">For example, PGE2, one of the major products of COX-2, which is usually inhibited by NSAIDs, is involved in:</p>
							<ul class="list-unstyled">
								<li><strong>A lipid mediator class switch<span class="tooltips"><sup>2</sup></strong></li>
								<li><strong>A macrophage phenotype switch<span class="tooltips"><sup>2</sup></strong></li>
								<li><strong>A neutrophil phenotype switch<span class="tooltips"><sup>7</sup></strong></li>
							</ul>
						</div>
						<div class="img-wrap-border">
							<img class="d-none d-md-block" src="@img/Heel-Microsite_Illustration-1_v1.svg" alt="">
							<img class="d-md-none" src="@img/Heel-Microsite_Mobile-Illustration-1_v1.svg" alt="">
						</div>
						<div class="caption">Abbreviations: COX, cyclooxygenase; LOX, lipoxygenase; LTs, leukotrienes; PGs, prostaglandins; PGE2, prostaglandin E2; SPMs, specialized proresolving mediators.</div>
						<div class="quote mx-auto pt-10 pb-5">
							<div class="quote__info"> NSAID treatment may have beneficial effects in the early phase of inflammation by preventing prostanoid production, but may also be “resolution-toxic,” by disrupting the production of anti-inflammatory prostaglandins and lipoxins.<span class="tooltips"><sup>2</sup></span></div>
						</div>
						<div class="separator pb-14 pt-8 pb-xl-6 pt-xl-4">
							<img src="@img/Divider-2.svg" alt="">
						</div>
					</div>
				</div>
			</div>
		</section>
		<section class="multitarget-drugs">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="h2 mb-3">MULTITARGET DRUGS PROVIDE A BETTER SOLUTION FOR COMPLEX PROCESSES LIKE INFLAMMATION RESOLUTION</div>
						<div class="img-wrap-border d-flex">
							<div class="img-wrap d-md-none">
								<img src="@img/Heel-Microsite_Animation2.svg" alt="">
							</div>
							<div class="img-wrap d-none d-md-block">
								<img src="@img/multitarget-drugs-1.svg" alt="">
							</div>
							<div class="img-wrap  d-none d-md-block">
								<img src="@img/multitarget-drugs-2.svg" alt="">
							</div>
						</div>
						<div class="caption d-none d-md-block">Abbreviations: COX-2, cyclooxygenase 2; FPR2, formyl peptide receptor 2; LTB4, leukotriene B4; LTAH, leukotriene A4 hydrolase; LXA4, lipoxin A4; PGE2, prostaglandin E2.</div>
						<div class="caption d-md-none">Abbreviations: COX-2, cyclooxygenase 2; PGE2, prostaglandin E2.</div>
						<div class="multitarget-drugs__info d-flex flex-column flex-lg-row justify-content-between pt-7 pb-6">
							<ul class="list-unstyled mb-0">
								<li><strong>Single-target drugs are designed to target a single biological entity (usually a protein) with high selectivity, not taking interactions with other targets into consideration</strong></li>
								<li><strong>Due to network complexity of disease biology, single-target drugs may have unwanted “ripple” effects on other “off-target” entities</strong></li>
								<li><strong>These “ripple” effects can potentially cause side effects, limiting the effective dose and effectiveness of the single-target drug</strong></li>
							</ul>
							<ul class="list-unstyled mb-0 d-none d-md-block">
								<li><strong>Multitarget drugs can target a larger part of the signaling network</strong></li>
								<li><strong>They can balance signaling inhibition with promotion by targeting selected synergistic pathways</strong></li>
								<li><strong>The synergistic effect of multiple targets across the signaling network allows to reduce pharmacological doses and possible side effects</strong></li>
							</ul>
						</div>
						<div class="mobile__info d-md-none">
							<div class="img-wrap">
								<img src="@img/Heel-Microsite_Animation3_v2.svg" alt="">
							</div>
							<div class="caption d-md-none">Abbreviations: COX-2, cyclooxygenase 2; FPR2, formyl peptide receptor 2; LTB4, leukotriene B4; LTAH, leukotriene A4 hydrolase; LXA4, lipoxin A4; PGE2, prostaglandin E2.</div>
							<div class="multitarget-drugs__info pt-7 pb-6">
								<ul class="list-unstyled mb-0">
									<li><strong>Multitarget drugs can target a larger part of the signaling network</strong></li>
									<li><strong>They can balance signaling inhibition with promotion by targeting selected synergistic pathways</strong></li>
									<li><strong>The synergistic effect of multiple targets across the signaling network allows to reduce pharmacological doses and possible side effects</strong></li>
								</ul>
							</div>
						</div>
						<p>Traumeel is a combination of natural ingredients in low concentration, designed to have multiple targets. Therefore, its mode of action is much broader compared to synthetic drugs. With modern technologies, such as single-molecule transcriptome sequencing and bioinformatics, investigating the action on thousands of signaling events simultaneously is possible.</p>
						<div class="separator pb-14 pt-8 pb-xl-6 pt-xl-4">
							<img src="@img/Divider.svg" alt="">
						</div>
					</div>
				</div>
			</div>
		</section>
		<section class="traumeel-well-established">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="h2 mb-4">TRAUMEEL HAS A WELL-ESTABLISHED EFFICACY AND SAFETY PROFILE</div>
						<div class="raumeel-well-established__wrapper">
							<div class="raumeel-well-established__info">
								<div class="raumeel-well-established__item">
									<ul class="list-unstyled">
										<li>Complex regulation of the <strong>inflammation process</strong> (granulocytes, lymphocytes, platelets and endothelial cells)<span class="tooltips"><sup>8</sup></span></li>
									</ul>
									<div class="h3">In vitro</div>
								</div>
								<div class="raumeel-well-established__item">
									<ul class="list-unstyled">
										<li><strong>Acute and chronic inflammation, edema</strong> (swelling and local inflammation)<span class="tooltips"><sup>9, 10</sup></span></li>
										<li><strong>Gene expression</strong> changes in inflammation (wound-healing model)<span class="tooltips"><sup>11</sup></span></li>
									</ul>
									<div class="h3">In vivo</div>
								</div>
								<div class="raumeel-well-established__item">
									<ul class="list-unstyled">
										<li><strong>Acute sprains</strong> of the ankle<span class="tooltips"><sup>12</sup></span></li>
										<li><strong>Acute musculoskeletal injuries</strong><span class="tooltips"><sup>13</sup></span></li>
										<li>Knee <strong>osteoarthritis</strong> (+ Zeel T)<span class="tooltips"><sup>14</sup></span></li>
									</ul>
									<div class="h3">Clinical vs placebo</div>
								</div>
								<div class="raumeel-well-established__item">
									<ul class="list-unstyled">
										<li>Vs <strong>diclofenac gel</strong><span class="tooltips"><sup>15,16</sup></span> and injectable <strong>NSAIDs</strong><span class="tooltips"><sup>17</sup></span></li>
										<li><strong>Tendinopathy</strong>,<span class="tooltips"><sup>16</sup></span> <strong>epicondylitis</strong><span class="tooltips"><sup>17</sup></span> and injuries of various origins<span class="tooltips"><sup>15</sup></span></li>
									</ul>
									<div class="h3">Clinical vs NSAIDs</div>
								</div>
							</div>
							<img class="traumeel-cross" src="@img/mg.png" alt="">
							<img class="traumeel-loader" src="@img/spinner-logo-1.png" alt="">
						</div>
					</div>
				</div>
			</div>
		</section>
		<section class="inflammation-resolution pt-12 pt-xl-22 pb-12">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="h2 mb-3">TRAUMEEL HAS DEMONSTRATED EFFECTS ON THE MEDIATORS AND CELLS INVOLVED IN INFLAMMATION RESOLUTION</div>
						<img class="img-wrap-border d-none d-md-block" src="@img/Heel-Microsite_Illustration-4_v1.svg" alt="">
						<img class="img-wrap-border d-md-none" src="@img/Heel-Microsite_Mobile-Illustration-4_v1.svg" alt="">
						<div class="caption">Abbreviations: COX-2, cyclooxygenase 2; IL-1β, interleukin 1β; IL-10, interleukin 10; LTB4, leukotriene B4; MMP13, matrix metalloproteinase 13; NF-κΒ, nuclear factor κΒ; PGD2, prostaglandin D2; TNF-α, tumor necrosis factor α; TGF-β, transforming growth factor β.</div>
						<div class="separator pt-8 pb-6">
							<img src="@img/Divider.svg" alt="">
						</div>
						<div class="h2 pt-4">FORTHCOMING EVENTS</div>
						<p class="text-blue-accent">Please contact your Heel medical representative to find out about forthcoming events on inflammation resolution in your area.</p>
					</div>
				</div>
			</div>
		</section>
		<section class="references pt-15 pb-18">
			<div class="container">
				<div class="row">
					<div class="col">
						<div class="h3 mb-3">REFERENCES</div>
						<div class="references__info d-flex flex-column flex-lg-row justify-content-between">
							<ol>
								<li>Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101. doi:10.1038/nature13479.</li>
								<li>Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset? Front Immunol. 2016;7:160. doi:10.3389/fimmu.2016.00160.</li>
								<li>Feehan KT, Gilroy DW. Is resolution the end of inflammation? Trends Mol Med. 2019;25(3):198-214. doi:10.1016/j.molmed.2019.01.006.</li>
								<li>Jones HR, Robb CT, Perretti M, Rossi AG. The role of neutrophils in inflammation resolution. Semin Immunol. 2016;28(2):137-145. doi:10.1016/j.smim.2016.03.007.</li>
								<li>De Oliveira S, Rosowski EE, Huttenlocher A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat Rev Immunol. 2016;16(6):378-391. doi:10.1038/nri.2016.49.</li>
								<li>Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15(8):551-567. doi:10.1038/nrd.2016.39.</li>
								<li>Loynes CA, Lee JA, Robertson AL, et al. PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. Sci Adv. 2018;4(9):eaar8320. doi:10.1126/sciadv.aar8320.</li>
								<li>Cesnulevicius K. The bioregulatory approach to work-related musculoskeletal disorders: using the multicomponent ultra low-dose medication Traumeel to target the multiple pathophysiological processes of the disease. Altern Ther Health Med. 2011;17(suppl 2):S8-S17.</li>
								<li>Lussignoli S, Bertani S, Metelmann H, Bellavite P, Conforti A. Effect of Traumeel S, a homeopathic formulation, on blood-induced inflammation in rats. Complement Ther Med. 1999;7(4):225-230. doi: 10.1016/S0965-2299(99)80006-5.</li>
								<li>Conforti A, Bertani S, Metelmann H, Chirumbolo S, Lussignoli S, Bellavite P. Experimental studies on the anti-inflammatory activity of a homeopathic preparation. Biomed Ther. 1997;15(1):28-31.</li>
							</ol>
							<ol start="11">
								<li>St. Laurent G III, Seilheimer B, Tackett M, et al. Deep sequencing transcriptome analysis of murine wound healing: effects of a multicomponent, multitarget natural product therapy-Tr14. Front Mol Biosci. 2017;4:57. doi:10.3389/fmolb.2017.00057.</li>
								<li>Zell J, Connert WD, Mau J, Feuerstake G. Treatment of acute sprains of the ankle: a controlled double-blind trial to test the effectiveness of a homeopathic ointment. Biol Ther. 1989;7(1):1-6.</li>
								<li>Böhmer D, Ambrus P. Treatment of sports injuries with Traumeel ointment: a controlled double-blind study. Biol Ther. 1992;10(4):290-300.</li>
								<li>Lozada CJ, del Rio E, Reitberg DP, Smith RA, Kahn CB, Moskowitz RW. A double-blind, randomized, saline-controlled study of the efficacy and safety of co-administered intra-articular injections of Tr14 and Ze14 for treatment of painful osteoarthritis of the knee: the MOZArT trial. Eur J Integr Med. 2017;13:54-63. doi:10.1016/j.eujim.2017.07.005.</li>
								<li>González de Vega C, Speed C, Wolfarth B, González J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract. 2013;67(10):979-989. doi:10.1111/ijcp.12219.</li>
								<li>Schneider C, Klein P, Stolt P, Oberbaum M. A homeopathic ointment preparation compared with 1% diclofenac gel for acute symptomatic treatment of tendinopathy. Explor J Sci Heal. 2005;1(6):446-452. doi:10.1016/j.explore.2005.08.010.</li>
								<li>Birnesser H, Oberbaum M, Klein P, Weiser M. The homeopathic preparation Traumeel S compared with NSAIDs for symptomatic treatment of epicondylitis. J Musculoskelet Res. 2004;8(2 & 3):119-128. doi:10.1142/S0218957704001284.</li>
							</ol>
						</div>
					</div>
				</div>
			</div>
		</section>
	</main>
	@@include('html/footer.html',{})
	<!-- @@include('html/cookies.html',{}) -->
	<script src="js/libs.min.js"></script>
	<script src="js/main.min.js"></script>

</body>

</html>